Digital Health Technology for Heart Failure Diagnostic Monitoring

Julie Thompson
Boston Scientific
Friday, December 4, 2020 - 1:25pm to 2:25pm
Zoom

I will describe my experience working in the area of algorithm development for implantable medical devices designed to improve heart failure patient management.  Signs and symptoms have been the hallmark of clinical assessment of heart failure (HF) patients. Current HF management takes a reactive approach, relying on patients recognizing symptoms and seeking help. However, patients often do not recognize their symptoms, resulting in late identification of a worsening condition which often results in hospitalization.  HeartLogic™ monitors patients’ HF status by assessing objective information from multiple physiological trends that are associated with common signs and symptoms of HF. HeartLogic fuses information from individual trends into a single diagnostic index and alerts clinicians when the patient’s condition changes in the worsening direction, enabling more timely ambulatory remote patient management.  HeartLogic is the first and only FDA approved Heart Failure Diagnostic in implantable cardiac therapy devices with remote alert capability. 

Julie is an R&D Director at Boston Scientific Corporation where she leads a team of scientists and engineers focused on developing diagnostic and therapy technology for improved cardiac patient management.  Julie joined Boston Scientific (previously Guidant Corporation) in 2001 after completing her PhD in electrical engineering at the University of Michigan.  She began her career as a research scientist focused on tachyarrhythmia algorithms, and subsequently transitioned to research management roles.  In 2005 Julie took on leadership of a team focused on developing diagnostic technology for heart failure monitoring.  She led this group through research and design of multiple diagnostic features that have been commercialized, including a novel multi-sensor diagnostic monitoring technology, HeartLogic™, proven to effectively detect early signs of worsening heart failure in patients indicated for an implantable cardiac rhythm management therapy device.